***_Please note, this table is being populated. If anyone interested for their paper to be included in this community resource, please send us your paper title_.**




**Review of Pharmaceutical Research**
| Authors |Data Type | Methodology|
| :---  | :--- | :--- |
[Zhavoronkov et al.](https://chemrxiv.org/ndownloader/articles/11829102/versions/2/export_pdf) [1]|Crystal structure,homology modelling,and co-crystallisedligands|The authors utilised generative models togenerate the molecules for the 3C-like protease that can actas potential inhibitors for SARS-CoV-2.|
[Hofmarcher et al.](https://arxiv.org/pdf/2004.00979) [2]|Drug-discovery databases|In this work, authors utilise ChemAI, a DNN trainedon million of data pints across 3.2 million of molecules, forscreening favourable inhibitors from the ZINC database for SARS-CoV-2.|
[Beck et al.](https://www.sciencedirect.com/science/article/pii/S2001037020300490) [3]|SMILES strings and amino acids sequences|Authors utilise a pre-trained drug-target interaction modelto predict commercially available antiviral drugs for COVID-19|




**References**

**[1]** Zhavoronkov, Alex, et al. "Potential COVID-2019 3C-like protease inhibitors designed using generative deep learning approaches." Insilico Medicine Hong Kong Ltd A 307 (2020).

**[2]** Hofmarcher, Markus, et al. "Large-scale ligand-based virtual screening for SARS-CoV-2 inhibitors using deep neural networks." Available at SSRN 3561442 (2020).

**[3]** Beck, Bo Ram, et al. "Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model." Computational and Structural Biotechnology Journal (2020).


